High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies

Fadi F. Hamdan, Candace T. Myers, Patrick Cossette, Philippe Lemay, Dan Spiegelman, Alexandre Dionne Laporte, Christina Nassif, Ousmane Diallo, Jean Monlong, Maxime Cadieux-Dion, Sylvia Dobrzeniecka, Caroline Meloche, Kyle Retterer, Megan T. Cho, Jill A. Rosenfeld, Weimin Bi, Christine Massicotte, Marguerite Miguet, Ledia Brunga, Brigid M. ReganKelly Mo, Cory Tam, Amy Schneider, Georgie Hollingsworth, David R. FitzPatrick, Alan Donaldson, Natalie Canham, Edward Blair, Bronwyn Kerr, Andrew E. Fry, Rhys H. Thomas, Joss Shelagh, Jane A. Hurst, Helen Brittain, Moira Blyth, Robert Roger Lebel, Erica H. Gerkes, Laura Davis-Keppen, Quinn Stein, Wendy K. Chung, Sara J. Dorison, Paul J. Benke, Emily Fassi, Nicole Corsten-Janssen, Erik-Jan Kamsteeg, Frederic T. Mau-Them, Ange-Line Bruel, Alain Verloes, Katrin Ounap, Monica H. Wojcik, Deciphering Developmental Disorders Study

    Research output: Contribution to journalArticleAcademicpeer-review

    339 Citations (Scopus)
    56 Downloads (Pure)

    Abstract

    Developmental and epileptic encephalopathy (DEE) is a group of conditions characterized by the co-occurrence of epilepsy and intellectual disability (ID), typically with developmental plateauing or regression associated with frequent epileptiform activity. The cause of DEE remains unknown in the majority of cases. We performed whole-genome sequencing (WGS) in 197 individuals with unexplained DEE and pharmaco-resistant seizures and in their unaffected parents. We focused our attention on de novo mutations (DNMs) and identified candidate genes containing such variants. We sought to identify additional subjects with DNMs in these genes by performing targeted sequencing in another series of individuals with DEE and by mining various sequencing datasets. We also performed meta-analyses to document enrichment of DNMs in candidate genes by leveraging our WGS dataset with those of several DEE and ID series. By combining these strategies, we were able to provide a causal link between DEE and the following genes: NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2, and SNAP25. Overall, we established a molecular diagnosis in 63/197 (32%) individuals in our WGS series. The main cause of DEE in these individuals was de novo point mutations (53/63 solved cases), followed by inherited mutations (6/63 solved cases) and de novo CNVs (4/63 solved cases). De novo missense variants explained a larger proportion of individuals in our series than in other series that were primarily ascertained because of ID. Moreover, these DNMs were more frequently recurrent than those identified in ID series. These observations indicate that the genetic landscape of DEE might be different from that of ID without epilepsy.

    Original languageEnglish
    Pages (from-to)664-685
    Number of pages22
    JournalAmerican Journal of Human Genetics
    Volume101
    Issue number5
    DOIs
    Publication statusPublished - 2-Nov-2017

    Keywords

    • SEVERE INTELLECTUAL DISABILITY
    • NOGO-B RECEPTOR
    • CIS-PRENYLTRANSFERASE
    • DIPHOSPHATE SYNTHASE
    • MEDICAL GENETICS
    • STRUCTURAL BASIS
    • DISORDERS
    • DISEASE
    • GLYCOSYLATION
    • CHILDREN

    Fingerprint

    Dive into the research topics of 'High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies'. Together they form a unique fingerprint.

    Cite this